BerGenBio ASA (BRRGF) has released an update.
BerGenBio ASA has received a positive recommendation from the DSMB to begin the second dose level in the Phase 2a trial of BGBC016 for NSCLC patients with STK11 mutations, after confirming safety at the highest dose tested in Phase 1b. The trial, which evaluates the efficacy of bemcentinib in combination with pembrolizumab and chemotherapy, is a priority for the company, with an interim analysis expected in the latter half of the year. BerGenBio focuses on developing bemcentinib, a potential first-in-class selective AXL inhibitor, for unmet medical needs including certain lung cancers.
For further insights into BRRGF stock, check out TipRanks’ Stock Analysis page.
